Holland In a market under strong pressures to contain costs, launching innovative products in a crowded market can be a challenge. Novo Nordisk GM Sanne Groenemeijer believes his organization’s willingness to try various solutions has helped them to maintain their dominant position as the market leader in diabetes. Since you took…
Chiesi Chiesi is preparing to market two first in class products: the first approved stem cell treatment in Europe, and the first approved gene-therapy, developed in the Netherlands by partner UniQure. General Manager Nether Maurits Huigen discusses the challenges his affiliate is facing to bringing these pioneering products to market, along…
pharmaceuticals Dr Martin Favle, Chairman of Bogin – the Dutch Generic Medicine Industry Association, representing the interests of the generic medicines industry in the Netherlands – shares his fears about slow growth in the Dutch generics market and the state of the biosimilars market. You were quoted in the media last year saying ‘2014 was a…
universal healthcare Berlin Pharmaceutical Industry’s CEO, Amal Naj, explains how he has grown the company, its next regional and medical targets, and his vision for its future. What has led to Berlin Pharmaceutical’s success over the last five years? In 2010, the market was going through a major transition due to the progressive…
government PharmaBoardroom met the Secretary General of the Thai FDA and the Senior Expert on Pharmaceutical Standards at the FDA. They explained the FDA’s role in Thailand’s pharma market, what the organization is doing for Thai copyright rights, how it is promoting international investment and integration within the ASEAN Economic Community. Please introduce…
Puerto Rico Puerto Rico’s healthcare insurance market is the first in Latin America in terms of penetration and sixth in terms of premium volume. Ángela Weyne, Insurance Commissioner of Puerto Rico, discusses how recent amendments to the Affordable Care Act (ACA) have been implemented locally, how she is spurring healthy competition among…
healthcare In the past, the Moroccan pharmaceutical sector primarily served local needs. Now it is ramping up its research and development capabilities, looking outwards to global markets, developing partnerships with other African countries, and beginning to think about social programs such as public access to healthcare. “[Morocco’s] success grew from a…
regulation Sevi Firat, Founding Partner of Firat Izgi discusses the legal challenges facing pharmaceutical companies looking to penetrate the healthcare market in Turkey, the evolution of the legal landscape and her expectations for the industry’s future. With pricing and regulations as the major challenges facing players within the Turkish pharma and…
investment The new government of Mauritius has chosen pharmaceuticals, healthcare and life sciences as priorities for the country’s innovation economy. Pharmaboardroom spoke with Ameenah Gurib Fakim, president of the Republic of Mauritius, who outlined her country’s strengths, and the challenge of replacing the country’s conventional “sun and sand” image with life sciences. Mauritius’ successful growth…
R&D Today’s Thai pharmaceutical market requires companies to adapt new leadership styles and carry new medicines in order to adjust to the needs of patients and clients. T. Man Pharma’s motto: “committed, innovative and developing quality pharmaceutical products to meet international standards” is what the director of sales and marketing, and…
Boehringer Ingelheim Sirilak Suteekul explains the organization’s success in Thailand over the last couple of years, Thailand’s untapped potential as a regional center in Southeast Asia and how innovation adds value to society. As managing director of the organization for nearly two years, what have been your major challenges and accomplishments since…
hematology Dante Castillo, managing director of Haemonetics Puerto Rico, explains the acquisition of Pall Life Science’s blood division and how the affiliate can focus on R&D as a new untapped area of potential, a unique asset in the country typically better known for manufacturing. How did the transition from Pall Life…
See our Cookie Privacy Policy Here
